LSE:GSKPharmaceuticals
GSK (LSE:GSK) Stock Could Be Below Fair Value Following mRNA Flu Vaccine Progress
GSK stock has delivered a roughly 54.5% total return over the past 5 years, yet recent weakness and a high value score suggest the market may still be pricing the pharmaceutical group cautiously. Investors now have to reconcile a solid longer term track record with a share price that screens as cheap on broader valuation checks.
Around 54.5% total return over 5 years points to meaningful long run value creation for holders who stayed invested.
Progress on cancer therapies and an mRNA flu...